Primo Biotechnology Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $7.43M

  • Investors
  • 2

Primo Biotechnology General Information

Description

Operator of a molecular imaging platform intended to provide an accurate diagnosis of cancer. The company's platform specializes in non-invasive radiopharmaceutical imaging technology to detect early-stage colorectal cancer, esophageal cancer, and lung adenocarcinoma, enabling doctors to make informed decisions, personalize and expedite cancer care.

Contact Information

Website
www.primobt.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 14F, No. 167, Dunhua North Road, Songshan District
  • Taipei City
  • Taiwan
+886 02
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Other Healthcare Technology Systems
Drug Delivery
Corporate Office
  • 14F, No. 167, Dunhua North Road, Songshan District
  • Taipei City
  • Taiwan
+886 02

Primo Biotechnology Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Primo Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 02-Jul-2025 $7.43M Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-2023 Completed Generating Revenue
To view Primo Biotechnology’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Primo Biotechnology Patents

Primo Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240123097-A1 Dual-mode pharmaceutical composition for peptide-specific targeted positron emission tomography and boron neutron capture therapy and the use thereof Pending 26-Sep-2022
US-20230144805-A1 Methods of noninvasive detection and specific treatment for cancer metastasis Pending 10-Nov-2021

Primo Biotechnology Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Paragon Investment Venture Capital Minority
AVA Angels Angel Group Minority
To view Primo Biotechnology’s complete investors history, request access »

Primo Biotechnology FAQs

  • When was Primo Biotechnology founded?

    Primo Biotechnology was founded in 2021.

  • Where is Primo Biotechnology headquartered?

    Primo Biotechnology is headquartered in Taipei City, Taiwan.

  • What industry is Primo Biotechnology in?

    Primo Biotechnology’s primary industry is Diagnostic Equipment.

  • Is Primo Biotechnology a private or public company?

    Primo Biotechnology is a Private company.

  • What is Primo Biotechnology’s current revenue?

    The current revenue for Primo Biotechnology is .

  • How much funding has Primo Biotechnology raised over time?

    Primo Biotechnology has raised $9.9M.

  • Who are Primo Biotechnology’s investors?

    Paragon Investment and AVA Angels have invested in Primo Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process